Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
Interventions: Testosterone Enanthate, Finasteride, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Prostate Cancer
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sarcopenia, Hypogonadism, Muscular Diseases
Interventions: Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation); Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions: Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment, Survey Administration, Testosterone Enanthate, Testosterone Cypionate; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Aging
Interventions: Placebo, Testosterone, Anastrazole, Dutasteride; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Long QT Syndrome
Interventions: Testosterone, Progesterone, Placebo, Ibutilide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 65 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostate Cancer
Interventions: GTx-758 125 mg, GTx-758 250 mg; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 26
States / cities: Burbank, California • Los Angeles, California • San Bernardino, California + 21 more

Conditions: Obesity and Hypogonadism
Interventions: Testosterone, Lifestyle Therapy, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years to 85 Years · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer
Interventions: Carboplatin, Docetaxel, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity; Endocrine, Hormone Disturbance
Interventions: Not listed
Lead sponsor: Precision Analytical, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 144,561 participants
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: McMinnville, Oregon

Conditions: Transgender Persons
Interventions: Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sarcopenia
Interventions: Testosterone injection, Testosterone gel, Medrol; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years to 85 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries, Central Nervous System Diseases, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions: Testosterone Enanthate, Finasteride, Placebo injection, Placebo pill; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Gainesville, Florida • Tampa, Florida

Conditions: Bone Metabolism
Interventions: testosterone cypionate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 30 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause
Interventions: Premarin® (oral) vs. Alora® (transdermal); Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 42 Years to 70 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Male Hypogonadism
Interventions: Oral testosterone undecanoate (containing 300 mg T); Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Torrance, California

Conditions: Cancer of the Prostate
Interventions: BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo; Drug
Lead sponsor: BHR Pharma, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more

Conditions: Osteoarthritis
Interventions: Blood Draw; Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Klinefelter Syndrome, Trisomy X, XYY Syndrome, XXXY and XXXXY Syndrome, Xxyy Syndrome, Xyyy Syndrome, Xxxx Syndrome, Xxxxx Syndrome, Xxxyy Syndrome, Xxyyy Syndrome, Xyyyy Syndrome, Male With Sex Chromosome Mosaicism
Interventions: Assessments of Development and Growth; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Weeks to 13 Months
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Hypogonadism
Interventions: Acyline, Placebo Gel, Placebo Tablet, Testosterone Gel, Arimidex; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hypogonadism
Interventions: Testosterone enanthate auto-injector; Combination Product
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • New York, New York • Columbus, Ohio

Conditions: Infant, Premature, Infant, Very Low Birth Weight
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 1 Minute to 72 Hours
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypogonadism, Male, End Stage Renal Disease (ESRD), Kidney Transplant
Interventions: Testosterone Replacement Therapy; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

5-Alpha Reductase and Anabolic Effects of Testosterone

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

TOM: Testosterone in Older Men With Sarcopenia

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Lifestyle Intervention and Testosterone Replacement in Obese Seniors

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Data Mining: Precision Analytical Retrospective Data Correlation

Effect of Testosterone Treatment on Drug Metabolism and Transport

Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men

Testosterone Plus Finasteride Treatment After Spinal Cord Injury

The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa

A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women

Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

Effects of Osteoarthritis Pain, Morphine, and Placebo on Neuroendocrine Function in Men

The eXtroardinarY Babies Study: Natural History of Health and Neurodevelopment in Infants and Young Children With Sex Chromosome Trisomy

Cardiovascular Outcomes of Low Testosterone

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

Testosterone and Cortisol Levels in Infants

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation